Annual EBITDA
-$153.28M$15.49M-11.24%
Summary
- Current Value
- As of today, ERAS annual EBITDA is -$153.28M, down -11.24% on
- Historical Performance
- ERAS annual EBITDA is down -60.15% over the past 3 years, and down -1080.55% over the past 5 years
- All-Time High Comparison
- ERAS annual EBITDA is currently -1080.55% below its historical high of -$12.98M set on
- 3-Year Low Comparison
- ERAS annual EBITDA is at its 3-year low
- Sector Comparison
- ERAS annual EBITDA is higher than 11.13% of companies in Healthcare sector
EBITDA Chart
Add series to chart1/6
Series
SUGGESTED SERIES
Performance
| Metric | Date | Value | 1Y | 3Y | 5Y | 15Y |
|---|---|---|---|---|---|---|
| Annual EBITDA | -$153.28M | -11.2% | -60.1% | -1080.5% | -1080.5% | |
| Quarterly EBITDA | -$31.79M | +12.7% | +12.2% | -188.4% | -34.1% | |
| TTM EBITDA | -$131.32M | +13.2% | +5.1% | -213.5% | -453.8% | |
| Price | $7.51 | +289.9% | +80.4% | – | – | |
| PE Ratio | - | – | – | – | – | |
| Annual Revenue | $0.00 | 0.0% | 0.0% | 0.0% | 0.0% | |
| Annual EPS | -$0.69 | +17.0% | +32.9% | -583.2% | -583.2% | |
| -$157.09M | -11.0% | -62.7% | -1081.6% | -1081.6% | ||
| Annual Net Income | -$161.65M | -29.3% | -31.7% | -1242.6% | -1242.6% |
EBITDA Highs
| Period | High | Date | Current |
|---|---|---|---|
| 3Y | -$137.79M | -11.2% | |
| 5Y | -$36.97M | N/A | -314.6% |
| All | -$12.98M | -1080.5% |
EBITDA Lows
| Period | Low | Date | Current |
|---|---|---|---|
| 3Y | -$153.28M | at low | |
| 5Y | -$153.28M | at low | |
| All | -$153.28M | at low |
EBITDA History
| Year | Value | Change |
|---|---|---|
| -$153.28M | -11.2% | |
| -$137.79M | +3.5% | |
| -$142.81M | -49.2% |
| Year | Value | Change |
|---|---|---|
| -$95.71M | -158.9% | |
| -$36.97M | -184.7% | |
| -$12.98M | - |
FAQ
What is the current annual EBITDA of ERAS?
As of today, ERAS annual EBITDA is -$153.28M
What is 1-year change in ERAS annual EBITDA?
ERAS annual EBITDA is down -11.24% year-over-year
What is 3-year change in ERAS annual EBITDA?
ERAS annual EBITDA is down -60.15% over the past 3 years
How far is ERAS annual EBITDA from its all-time high?
ERAS annual EBITDA is currently -1080.55% below its historical high of -$12.98M set on December 31, 2019
How does ERAS annual EBITDA rank versus sector peers?
ERAS annual EBITDA is higher than 11.13% of companies in Healthcare sector
When is ERAS next annual earnings release?
The next annual earnings release for ERAS is on
Quarterly EBITDA
-$31.79M$1.95M-6.55%
Summary
- Current Value
- As of today, ERAS quarterly EBITDA is -$31.79M, down -6.55% on
- Historical Performance
- ERAS quarterly EBITDA is up +12.66% year-over-year, and up +12.16% over the past 3 years
- All-Time High Comparison
- ERAS quarterly EBITDA is currently -344.63% below its historical high of -$7.15M set on
- 3-Year Low Comparison
- ERAS quarterly EBITDA is +76.82% above its 3-year low of -$137.15M reached on an earlier date
- Sector Comparison
- ERAS quarterly EBITDA is higher than 13.38% of companies in Healthcare sector
Performance
| Metric | Date | Value | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|
| Quarterly EBITDA | -$31.79M | -6.5% | +12.7% | +12.2% | -188.4% | |
| Annual EBITDA | -$153.28M | – | -11.2% | -60.1% | -1080.5% | |
| TTM EBITDA | -$131.32M | +3.4% | +13.2% | +5.1% | -213.5% | |
| Price | $7.51 | +211.4% | +289.9% | +80.4% | – | |
| PE Ratio | - | – | – | – | – | |
| Quarterly Revenue | $0.00 | 0.0% | 0.0% | 0.0% | 0.0% | |
| Quarterly EPS | -$0.11 | +9.8% | +2.4% | +63.3% | -23.3% | |
| -$32.55M | -6.3% | +12.6% | +11.9% | -191.6% | ||
| Quarterly Net Income | -$30.61M | +9.6% | +1.9% | +13.7% | -188.6% |
Quarterly EBITDA Highs
| Period | High | Date | Current |
|---|---|---|---|
| 1Y | -$29.84M | -6.5% | |
| 3Y | -$29.84M | -6.5% | |
| 5Y | -$19.46M | -63.4% | |
| All | -$7.15M | -344.6% |
Quarterly EBITDA Lows
| Period | Low | Date | Current |
|---|---|---|---|
| 1Y | -$34.88M | N/A | +8.9% |
| 3Y | -$137.15M | N/A | +76.8% |
| 5Y | -$137.15M | +76.8% | |
| All | -$137.15M | +76.8% |
Quarterly EBITDA History
FAQ
What is the current quarterly EBITDA of ERAS?
As of today, ERAS quarterly EBITDA is -$31.79M
What is ERAS quarterly EBITDA most recent change?
ERAS quarterly EBITDA was down -6.55% on September 30, 2025
What is 1-year change in ERAS quarterly EBITDA?
ERAS quarterly EBITDA is up +12.66% year-over-year
How far is ERAS quarterly EBITDA from its all-time high?
ERAS quarterly EBITDA is currently -344.63% below its historical high of -$7.15M set on June 30, 2020
How does ERAS quarterly EBITDA rank versus sector peers?
ERAS quarterly EBITDA is higher than 13.38% of companies in Healthcare sector
When is ERAS next earnings release?
The next earnings release for ERAS is on
TTM EBITDA
-$131.32M$4.61M+3.39%
Summary
- Current Value
- As of today, ERAS TTM EBITDA is -$131.32M, up +3.39% on
- Historical Performance
- ERAS TTM EBITDA is up +13.24% year-over-year, and up +5.11% over the past 3 years
- All-Time High Comparison
- ERAS TTM EBITDA is currently -453.75% below its historical high of -$23.71M set on
- 3-Year Low Comparison
- ERAS TTM EBITDA is +46.37% above its 3-year low of -$244.84M reached on
- Sector Comparison
- ERAS TTM EBITDA is higher than 12.75% of companies in Healthcare sector
Performance
| Metric | Date | Value | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|
| TTM EBITDA | -$131.32M | +3.4% | +13.2% | +5.1% | -213.5% | |
| Annual EBITDA | -$153.28M | – | -11.2% | -60.1% | -1080.5% | |
| Quarterly EBITDA | -$31.79M | -6.5% | +12.7% | +12.2% | -188.4% | |
| Price | $7.51 | +211.4% | +289.9% | +80.4% | – | |
| PE Ratio | - | – | – | – | – | |
| TTM Revenue | $0.00 | 0.0% | 0.0% | 0.0% | 0.0% | |
| TTM EPS | -$0.45 | +0.6% | +45.6% | +60.9% | -35.5% | |
| -$134.51M | +3.4% | +13.4% | +4.2% | -218.1% | ||
| TTM Net Income | -$127.69M | +0.5% | +19.8% | +7.5% | -221.2% |
TTM EBITDA Highs
| Period | High | Date | Current |
|---|---|---|---|
| 1Y | -$131.32M | at high | |
| 3Y | -$131.32M | at high | |
| 5Y | -$104.46M | -25.7% | |
| All | -$23.71M | -453.8% |
TTM EBITDA Lows
| Period | Low | Date | Current |
|---|---|---|---|
| 1Y | -$153.32M | N/A | +14.3% |
| 3Y | -$244.84M | +46.4% | |
| 5Y | -$244.84M | +46.4% | |
| All | -$244.84M | +46.4% |
TTM EBITDA History
FAQ
What is the current TTM EBITDA of ERAS?
As of today, ERAS TTM EBITDA is -$131.32M
What is ERAS TTM EBITDA most recent change?
ERAS TTM EBITDA was up +3.39% on September 30, 2025
What is 1-year change in ERAS TTM EBITDA?
ERAS TTM EBITDA is up +13.24% year-over-year
How far is ERAS TTM EBITDA from its all-time high?
ERAS TTM EBITDA is currently -453.75% below its historical high of -$23.71M set on March 31, 2020
How does ERAS TTM EBITDA rank versus sector peers?
ERAS TTM EBITDA is higher than 12.75% of companies in Healthcare sector
When is ERAS next earnings release?
The next earnings release for ERAS is on
EBITDA Formula
EBITDA = + + +
Data Sources & References
- ERAS Official Website www.erasca.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1761918/000119312525277625/0001193125-25-277625-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1761918/000095017025042682/0000950170-25-042682-index.htm
- ERAS Profile on Yahoo Finance finance.yahoo.com/quote/ERAS
- ERAS Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/eras